JP2017513945A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513945A5
JP2017513945A5 JP2017505687A JP2017505687A JP2017513945A5 JP 2017513945 A5 JP2017513945 A5 JP 2017513945A5 JP 2017505687 A JP2017505687 A JP 2017505687A JP 2017505687 A JP2017505687 A JP 2017505687A JP 2017513945 A5 JP2017513945 A5 JP 2017513945A5
Authority
JP
Japan
Prior art keywords
medicament according
dermal wound
wound
dermal
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505687A
Other languages
English (en)
Japanese (ja)
Other versions
JP6873387B2 (ja
JP2017513945A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050177 external-priority patent/WO2015157822A1/en
Publication of JP2017513945A publication Critical patent/JP2017513945A/ja
Publication of JP2017513945A5 publication Critical patent/JP2017513945A5/ja
Application granted granted Critical
Publication of JP6873387B2 publication Critical patent/JP6873387B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505687A 2014-04-16 2015-04-16 創傷治癒に対するａｐｃ類似体の使用 Active JP6873387B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2014901397A AU2014901397A0 (en) 2014-04-16 Treatment of abnormal cutaneous scarring
AU2014901397 2014-04-16
AU2014902900 2014-07-25
AU2014902900A AU2014902900A0 (en) 2014-07-25 Use of APC analogue for wound healing
PCT/AU2015/050177 WO2015157822A1 (en) 2014-04-16 2015-04-16 Use of apc analogue for wound healing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020031999A Division JP2020100648A (ja) 2014-04-16 2020-02-27 創傷治癒に対するａｐｃ類似体の使用

Publications (3)

Publication Number Publication Date
JP2017513945A JP2017513945A (ja) 2017-06-01
JP2017513945A5 true JP2017513945A5 (cg-RX-API-DMAC7.html) 2018-05-31
JP6873387B2 JP6873387B2 (ja) 2021-05-19

Family

ID=54323284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017505687A Active JP6873387B2 (ja) 2014-04-16 2015-04-16 創傷治癒に対するａｐｃ類似体の使用
JP2020031999A Withdrawn JP2020100648A (ja) 2014-04-16 2020-02-27 創傷治癒に対するａｐｃ類似体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020031999A Withdrawn JP2020100648A (ja) 2014-04-16 2020-02-27 創傷治癒に対するａｐｃ類似体の使用

Country Status (11)

Country Link
US (3) US20170035862A1 (cg-RX-API-DMAC7.html)
EP (1) EP3131572B1 (cg-RX-API-DMAC7.html)
JP (2) JP6873387B2 (cg-RX-API-DMAC7.html)
CN (1) CN106488773B (cg-RX-API-DMAC7.html)
AU (1) AU2015246656B2 (cg-RX-API-DMAC7.html)
CA (1) CA2946032C (cg-RX-API-DMAC7.html)
DK (1) DK3131572T3 (cg-RX-API-DMAC7.html)
ES (1) ES2890623T3 (cg-RX-API-DMAC7.html)
PL (1) PL3131572T3 (cg-RX-API-DMAC7.html)
PT (1) PT3131572T (cg-RX-API-DMAC7.html)
WO (1) WO2015157822A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
US20170042982A1 (en) 2014-04-16 2017-02-16 Zz Biotech Llc Treatment of abnormal cutaneous scarring
CN107619437B (zh) * 2017-11-07 2019-08-13 昆明医科大学 一种皮肤创伤修复肽whpp-oa1及其提纯方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
AU2467395A (en) 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
PL195642B1 (pl) 1997-04-28 2007-10-31 Lilly Co Eli Sposób przetwarzania wodnego roztworu aktywowanego białka C
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
CA2398929C (en) 2000-02-04 2011-05-31 The Scripps Research Institute Neuroprotective, antithrombotic and anti-flammatory uses of activated protein c (apc)
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
DE60111620T2 (de) 2000-03-28 2006-05-18 Eli Lilly And Co., Indianapolis Aktiviertes protein c zur behandlung von pankreatitis
EP1328622A2 (en) 2000-10-18 2003-07-23 Maxygen Aps Protein c or activated protein c-like molecules
AU2002302192B2 (en) * 2001-06-13 2007-08-16 Zz Biotech Llc Treatment and composition for wound healing
AU2003275948A1 (en) 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
SI1477166T1 (sl) 2003-04-28 2006-12-31 Biofrontera Bioscience Gmbh Uporaba riluzola, kombiniranega s primernimi pomoznimi in dodatnimi snovmi, za zdravljenje bolezni,za katere je znacilna hiperproliferacija keratinocitov, se zlasti nevrodermitisa in psoriaze
WO2005007820A2 (en) * 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20070224150A1 (en) 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
CA2612597C (en) 2005-06-24 2015-03-31 Drugrecure Aps Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
GR1005700B (el) 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
WO2008073603A2 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
CN101912450A (zh) 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
JP6273272B2 (ja) * 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
US20170042982A1 (en) 2014-04-16 2017-02-16 Zz Biotech Llc Treatment of abnormal cutaneous scarring

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL260852B (en) Methods, devices and systems for pulmonary delivery of active agents
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX386598B (es) Compuestos antibacterianos.
MX381599B (es) Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria
UA118558C2 (uk) Пептидна сполука
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MX2018005829A (es) Composiciones para tratar el cabello.
NI201600071A (es) Compuestos de inhibidor de autotaxina
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
JP2014530840A5 (cg-RX-API-DMAC7.html)
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
LT3219316T (lt) Riebalų rūgščių mišinys (r.r.g., riebalų rūgščių grupė), skirtas naudoti uždegiminių patologijų gydymui
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
JP2013231052A5 (cg-RX-API-DMAC7.html)
EA201792346A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc)
JP2017513945A5 (cg-RX-API-DMAC7.html)
JP2015516943A5 (cg-RX-API-DMAC7.html)
JP2017513944A5 (cg-RX-API-DMAC7.html)
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
KR101894521B9 (ko) 흉터치료를 위한 국소용 약학적 조성물